Search This Blog

Thursday, October 15, 2026

'Reuters: Iran Changes Hormuz Tactics to Keep Oil Prices High Before US Midterms'

 Iran has changed its tactics for attacking ships around the Strait of Hormuz to keep oil prices elevated and influence November’s U.S. midterm elections, two senior Iranian officials told Reuters.

The shift involves both the methods and frequency of attacks, alongside plans to extend operations into the Gulf of Oman and more distant waters.

The officials said Iran’s highest leadership had approved the strategy, with coordination across the ruling system.

“The aim is to frustrate efforts by the United States and its allies to bring down global oil prices,” one official said.

One of the officials said the revised tactics had been introduced about 10 days earlier against vessels deemed to have breached Tehran’s transit restrictions.

Neither disclosed the operational details.

Small Boats Replace Lost Radar Coverage

A U.S. military official confirmed a significant change in Iranian surveillance: the Islamic Revolutionary Guard Corps has begun deploying unarmed crews in small boats to locate targets, including American warships, after U.S. strikes destroyed much of Iran’s radar capability.

In an incident last week that had not previously been reported, American forces identified a dhow whose occupants were relaying targeting information to the IRGC, the official said.

U.S. forces ordered those aboard to leave before destroying the vessel. The official reported no casualties.

The same official said Iran’s reluctance to expose its surviving fast boats had limited its ability to stop rising oil exports through Hormuz after American strikes devastated its navy.

Attacks Spread Across Gulf Waters

Independent maritime data indicate that attacks on commercial shipping have reached their highest frequency since the war began.

At least five incidents involving tankers and other merchant vessels were recorded around Hormuz within 48 hours, including drone attacks, according to maritime security sources and reports to the U.K. navy-affiliated United Kingdom Maritime Trade Operations agency.

That pace broadly matched the escalation recorded on October 3-5, according to International Maritime Organization data.

Analysis of recent incident reports also suggests operations are spreading beyond the strait. Maritime security sources identified attacks in waters off Qatar and the United Arab Emirates.

The Iranian officials said the planned expansion would put vessels breaching Tehran’s restrictions at risk further afield.

Oil Prices Become an Election Lever

Hormuz carried roughly one-fifth of global oil and liquefied natural gas trade before the war.

Iranian restrictions, threats and attacks have sharply reduced shipping traffic and pushed up oil prices, although some exports continue.

Tehran began seeking control over passage after U.S. and Israeli strikes on Iran on February 28.

Washington has meanwhile maintained a naval blockade of Iranian ports and expanded sanctions to pressure Iran into an agreement ending the conflict.

The war, costing $3 billion a month, has become a campaign issue ahead of elections that will determine control of Congress.

President Donald Trump has said he will hold off on further attacks until after the vote.

One Iranian official described Tehran’s price strategy as deliberate obstruction: “Just when they think they are getting close to the point where prices will fall, we will push them away from it. This is a game of chess.”

Both officials said Iran was working toward preventing any vessel that violated its restrictions from crossing Hormuz.

The U.S. Navy-led Joint Maritime Information Center rated the threat to merchant shipping as severe, its second-highest category, in its Sunday assessment.

https://clashreport.com/world/articles/iran-changes-hormuz-tactics-to-keep-oil-prices-high-before-us-midterms-iekao5za9j

Nord Stream Sabotage Trial Begins With Explosive Allegations Against Ukraine

 by RFE/RL staff via OilPrice.com,

  • A German court is trying former Ukrainian officer Serhii Kuznetsov over his alleged role in coordinating the September 2022 Nord Stream pipeline sabotage.

  • German prosecutors allege the operation was conducted on behalf of Ukrainian state authorities, although Kyiv denies involvement and no Ukrainian political leadership role has been established.

  • The trial could intensify political disputes in Germany over continued military assistance to Ukraine, particularly among opposition parties critical of Berlin's support.

After four years of speculation, leaks, and briefings by anonymous sources, the world is finally about to hear evidence given publicly under oath in a German courtroom about how the Nord Stream gas pipelines were blown up - in a case that could prove politically explosive.

German prosecutors have identified seven Ukrainian suspects, but just one of them is in the dock in the trial beginning on October 14. He is named as Serhii K. in court documents that say he is suspected of being an accomplice to a war crime.

That classification has caused outrage. But German prosecutors have further raised the stakes by stating the suspects were operating "on behalf of state authorities in Ukraine."

Kyiv has always strictly denied any involvement in the attack, which damaged crucial energy infrastructure serving Germany - one of its most important military backers in its fight since Russia launched its full-scale invasion in February 2022.

Serhii K., who has been identified elsewhere as Serhiy Kuznetsov, says he is innocent.

'Two Crazy Military Men'

Nord Stream is majority-owned by Russia's state-controlled Gazprom and co-financed by major European energy companies. It was constructed to deliver Russian gas directly to Germany, bypassing transit states such as Ukraine and Poland, which had tense relations with Moscow.

The suspected sabotage and subsequent gas leaks happened in September 2022, rendering the pipelines as inoperable.

Western governments originally accused Russia of carrying out the blasts, but German investigators started forming a case that said a group of Ukrainian divers hired a yacht and planted explosives on the seabed.

They say Kuznetsov, a former military officer, was the ringleader.

"At the end of February 2022, he and other military personnel, on behalf of state authorities in Ukraine, developed the plan," says a summary of the indictment released by prosecutors. "The aim was to permanently halt gas deliveries via the pipelines and prevent Russia from using the revenue from the natural gas trade to finance its war efforts."

The prosecutors have not stated publicly the full extent of the alleged conspiracy.

The full indictment contains some further details, according to three German media outlets that say they have seen it: public-service TV station ARD and two print-era heavyweights, Sueddeutsche Zeitung and Die Zeit.

They all reported that, while in custody in Italy, Kuznetsov had phoned his wife in Kyiv and investigators were secretly listening in as he said he'd been advised by a lawyer that it was time to admit this had been "an official military operation." His commander should state that they were not just "two crazy military men."

Kuznetsov's Italian lawyer, Nicola Canestrini, has played down the importance of this evidence, saying there was "no smoking gun" in the case.

"It is hard to believe that, after Russia's war of aggression against Ukraine, a German court should hold a war crimes trial against a Ukrainian serviceman," he added in comments to RFE/RL.

The three German media outlets named Roman Chervinskiy as Serhii K.'s commander, and his name also appeared in multiple earlier media reports citing intelligence sources. Chervinskiy told RFE/RL's Ukrainian Service in July that "the Germans actually have no evidence whatsoever that Serhii took part in this operation, if it even took place."

Another suspect, identified by Germany as Vladimir Z., is currently in custody in Croatia, where he is fighting extradition. He was previously detained in Poland but was freed when a Polish judge ruled that if Ukraine were responsible for the Nord Stream attack, it was a "just" act.

A professional diver identified by his Polish lawyers as Volodymyr Zhuravlyov, he was working in Croatia as an adviser on a Hollywood movie about Nord Stream.

During the trial, the prosecution will have to lay out its evidence for a conspiracy and the full extent of it.

"That is the crucial question: How much came from the top of the Ukrainian political system or how much was prepared by some insiders in the intelligence service?" Stefan Meister, a specialist on Russia and Eastern Europe at the German Council on Foreign Relations, told RFE/RL.

"The key political question is the role of Zelenskyy and the presidential administration. And there we still have no proof that they were really involved," he added.

Kuznetsov's German lawyer, Jes Meyer-Lohkamp, said prosecutors "have not provided any direct, conclusive evidence of our client's involvement" and that the German court will have to determine whether Nord Stream was actually a legitimate military target.

The Hanseatic Higher Regional Court in Hamburg has scheduled two hearings every week until at least February, with no specified end date yet.

German Support For Ukraine

As the case unfolds, it will also feed into bitter disputes in Germany about ongoing support for Ukraine. The main opposition party, Alternative for Germany (AfD), is highly critical of this support and calls for close ties to Russia instead.

Evidence of Ukrainian involvement in the Nord Stream attack "would strengthen the AfD's argumentation against this support for Ukraine," said Meister. "They have all these narratives about Ukrainian corruption, a failed state.... It would resonate also in parts of German society."

The AfD has recently won key regional elections and is piling the pressure on Chancellor Friedrich Merz's government over Ukraine, immigration, and economic concerns.

Merz's response has been to double down on his current policies, including on Ukraine. Most recently, he was in Kyiv on October 4 with a new aid package including joint production of interceptors to shoot down Russian jet-powered drones.

Mikhaylo Honchar, head of the Kyiv-based Strategy XXI Global Studies Center, told RFE/RL this would likely continue regardless of what comes out at the trial.

"If you take into consideration real Russian policy, which is directed against the EU and NATO, and Russia's anti-German rhetoric, I think the government of Germany will avoid steps which would undermine the bilateral relationship [with Ukraine]", he said.

He added that the prosecution case was "absurd," citing German media reports that the attack may have been a Russian false-flag operation.

But in any case, Honchar said, a guilty verdict would be met with a clear response in Ukraine. "Many people will say: 'If our guys did it, they are heroes.'"

https://www.zerohedge.com/geopolitical/nord-stream-sabotage-trial-begins-explosive-allegations-against-ukraine

Arcutis started at Overweight by Cantor

Target $48

https://finviz.com/stock?t=ARQT&p=d

'UK must work with EU to counter China's EV dominance'

 UK Trade Minister Anas Sarwar stated on Thursday that London and Brussels must "work together and act in lockstep" to address China's dominance in the automotive industry.

"The more that the UK and the EU work together ... the better it is for both the UK and the European Union," Sarwar told Politico on the sidelines of the German-British Business Summit, adding that talks with European partners on tariffs for Chinese electric vehicles are ongoing. "We've got muscular protectionism on one side, we've got rapid expansionism on another side, and governments across the world of similar economy sizes to ourselves in Germany are having to work through what does that mean for our supply chains," Sarwar stressed.

Earlier this year, the bloc raised tariffs on Chinese-made electric vehicles from 7.8% to 35.3%

https://breakingthenews.net/Article/UK-must-work-with-EU-to-counter-China's-EV-dominance/67319372

WTI surges 3% amid Putin's threats

 The prices of oil futures erased earlier losses on Thursday, with the West Texas Intermediate (WTI) soaring 3% after Russian President Vladimir Putin promised to make Ukraine pay for striking the country's energy sector.

United States President Donald Trump's recently announced energy ceasefire seemingly fell through as both sides traded attacks. In addition, the latest data from the Energy Information Administration (EIA) and the American Petroleum Institute (API) pointed to declines in oil inventories, raising further concerns on the supply side.

WTI for settlements in November jumped 3.13% at 12:14 pm ET, going for $98.07 per barrel. At the same time, Brent for deliveries in December stood flat, selling at $106.17 per barrel.

https://breakingthenews.net/Article/WTI-surges-3-amid-Putin's-threats/67318482

Nasdaq reports network disruption

 Nasdaq reported a network disruption on Thursday affecting multiple multicast groups originating from its Carteret data center, warning customers of intermittent data gaps across its US equities feeds.

The disruption affected all of its US equities markets, including all hardware and software feeds for Nasdaq, Nasdaq Texas, and Nasdaq PSX, the exchange operator said.

Nasdaq advised clients to switch to their Chicago feeds as a backup, noting that those feeds remain unaffected. Customers experiencing data gaps were also urged to submit recovery requests for missing data. The exchange added that it was investigating the issue and would provide further updates as more information becomes available.

https://breakingthenews.net/Article/Nasdaq-reports-network-disruption/67317607

Oral Peptide Shows Durable Efficacy in Ulcerative Colitis

 An oral peptide that blocks the interleukin-23 receptor demonstrated durable long-term efficacy in patients with moderately to severely active ulcerative colitis, according to results from the phase IIb ANTHEM-UC trial.

During the long-term extension phase of the study, the majority of patients who remained on treatment with icotrokinra (Icotyde) were in clinical response, clinical remission, or endoscopic improvement at week 76, "all of the things we expect from a drug that works," said Maria Abreu, MD, of Cedars-Sinai Medical Center in Los Angeles, at the American College of Gastroenterology annual meeting in Nashville, Tennessee.

Patients receiving 100-mg, 200-mg, or 400-mg doses of icotrokinra had clinical response rates of 81.3%, 72.7%, and 72.7%, respectively; clinical remission rates of 56.3%, 59.1%, and 56.8%, with 97% corticosteroid-free; and endoscopic improvement rates of 64.6%, 68.2%, and 63.6%.

The original 12-week phase of the study, the results of which were published in the New England Journal of Medicine, showed that patients assigned to receive 100-mg, 200-mg, or 400-mg doses of the drug achieved clinical response rates of 55%, 58%, and 63%, respectively, compared with a rate of 27% in the placebo group (P<0.001 for all comparisons), meeting the study's primary endpoint.

In addition, a significantly greater proportion of patients receiving 400-mg icotrokinra achieved clinical remission, symptomatic remission, and endoscopic improvement at week 12 compared with placebo patients.

"Unsurprisingly, people who were naive for advanced therapies had higher response rates than those previously exposed," Abreu said. However, even patients previously exposed to advanced therapies had clinical remission rates over 50%, she pointed out.

Moreover, symptomatic remission was observed as early as week 4, with rates that were maintained or improved through week 76.

"So, it looks like over time that there is no fall-off," Abreu told MedPage Today. "People didn't lose the response. The ones that responded continue to do well. And that's another big issue in our field ... that patients do fine at the beginning of treatment, they lose response, and then it's all downhill from there."

"What's nice is that it is an oral drug, and we know it's safe," she added. "So, this could be a really nice advance for our patients."

Considering its safety, and the fact that it is an oral drug that generates early and durable responses, she suggested that icotrokinra will have a role as a first-line advanced therapy if approved for patients with ulcerative colitis.

Earlier this year, the FDA approved icotrokinra for adults and children ages 12 years and older with moderate or severe plaque psoriasis.

According to Abreu and co-authors, the mechanism of receptor blockade with this first-in-class drug contrasts with that of parenterally administered biologic agents that target circulating cytokines, including the p19 subunit of interleukin-23, such as risankizumab (Skyrizi), mirikizumab (Omvoh), and guselkumab (Tremfya), and the p40 subunit of interleukin-12 and interleukin-23, such as ustekinumab (Stelara).

ANTHEM-UC included adults with a diagnosis of ulcerative colitis at least 12 weeks before screening. Patients had to have moderately to severely active disease, defined as a modified Mayo score of at least 5 at baseline and a Mayo endoscopic subscore of at least 2 obtained during central review of the video endoscopy performed at screening.

In addition, participants had to have a history of glucocorticoid dependence; unacceptable side effects with or an inadequate response to oral glucocorticoids, azathioprine, or mercaptopurine; or a history of unacceptable side effects with or an inadequate response to at least one approved advanced therapy for ulcerative colitis at an approved dose.

A total of 252 participants at 115 sites underwent randomization, with 63 assigned to the 400-mg group, 62 to the 200-mg group, 64 to the 100-mg group, and 63 to the placebo group. Patients achieving a clinical response at week 28 were able to continue study treatment in the long-term extension phase.

Across the icotrokinra groups in the long-term extension phase, mean age was 40-46, 55-63% were men, and 66-71% were white.

Groups in the long-term extension phase were well matched, with the exception that more patients in the 400-mg cohort had extensive disease and were more likely to have received two or more classes of therapy in advance of the study.

A majority of participants (85%) stayed in the long-term extension study over 76 weeks.

Adverse events (AEs) were more frequent in the icotrokinra groups than the placebo group, including worsening of ulcerative colitis, upper respiratory tract infection, nasopharyngitis, headache, and arthralgia. However, the proportions of participants with one or more serious AEs or with an AE that led to discontinuation of the trial regimen were not higher in the icotrokinra groups versus the placebo group.

The phase III ICONIC-UC trial is evaluating icotrokinra in adults and adolescents with moderately to severely active ulcerative colitis.

Disclosures